ARIAD Pharma (ARIA) Updates on Iclusig Pricing and Reimbursement in France; Will Record Q2 Net Product Revenue

ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced that negotiations with the Economic Committee on Health Care Products in France regarding pricing and reimbursement for Iclusig® (ponatinib) have now concluded. As a result, ARIAD will record net product revenue related to cumulative shipments in France of approximately $25 million in the second quarter of 2016.

Iclusig has been available to patients in France since late 2012 through a pre-licensed sales mechanism called an ATU (temporary authorization of use). This mechanism allows patient access to potential life-saving drugs prior to full pricing and reimbursement approval.e/20160519005215/en/

You May Also Be Interested In

• Take-Two Interactive Software (TTWO) to Cut 5% Staff, Announces Cost Reduction Plan
• HubSpot (HUBS) Announces Departure of Chief Customer Officer; Promotes Existing Sales, Marketing, and Customer Success Leaders
• WRAP Technologies (WRAP) Provides Update on Operations and Timing of Q4 Report